Successful treatment of an EBV-positive HIV-associated polymorphic B-cell lymphoproliferative disorder by rituximab monotherapy
- PMID: 35844689
- PMCID: PMC9175691
- DOI: 10.1002/jha2.247
Successful treatment of an EBV-positive HIV-associated polymorphic B-cell lymphoproliferative disorder by rituximab monotherapy
Keywords: HIV; polymorphic B‐cell lymphoproliferative disorder; rituximab.
Conflict of interest statement
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.Mohamad Sabbah, Sylvain Choquet, Agathe Maillon, Clotilde Bravetti, Marine Baron, Frédéric Charlotte, and Damien Roos‐Weil performed, designed the research study, analyzed the data, and wrote the paper.
Figures

Similar articles
-
Iatrogenic immunodeficiency-associated lymphoproliferative disorder in a child with B-cell acute lymphoblastic leukemia.Pediatr Hematol Oncol. 2019 Aug;36(5):309-316. doi: 10.1080/08880018.2019.1637982. Epub 2019 Jul 17. Pediatr Hematol Oncol. 2019. PMID: 31314679
-
Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.Clin Cancer Res. 2003 May;9(5):1931-9. Clin Cancer Res. 2003. PMID: 12738752
-
Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial.Lancet Oncol. 2024 Mar;25(3):376-387. doi: 10.1016/S1470-2045(23)00649-6. Epub 2024 Jan 31. Lancet Oncol. 2024. PMID: 38309282
-
Primary Cutaneous Polymorphic EBV-Associated Posttransplant Lymphoproliferative Disorder After a Renal Transplant and Review of the Literature.Am J Dermatopathol. 2015 Oct;37(10):790-4. doi: 10.1097/DAD.0000000000000272. Am J Dermatopathol. 2015. PMID: 25747810 Review.
-
Successful Blinatumomab treatment in an allogeneic hematopoietic stem cell transplant recipient with EBV-related post-transplant lymphoproliferative disorder: A case report and literature review.Transpl Immunol. 2023 Oct;80:101895. doi: 10.1016/j.trim.2023.101895. Epub 2023 Jul 5. Transpl Immunol. 2023. PMID: 37414267 Review.
References
-
- Dharnidharka VR, Webster AC, Martinez OM, Preiksaitis JK, Leblond V, Choquet S. Post‐transplant lymphoproliferative disorders. Nat Rev Dis Primers. 2016;2:15088. - PubMed
-
- Nador RG, Chadburn A, Gundappa G, Cesarman E, Said JW, Knowles DM. Human immunodeficiency virus (HIV)‐associated polymorphic lymphoproliferative disorders. Am J Surg Pathol. 2003;27:293–302. - PubMed
-
- Trappe RU, Dierickx D, Zimmermann H. Response to rituximab induction is a predictive marker in B‐cell post‐transplant lymphoproliferative disorder and allows successful stratification into rituximab or R‐CHOP consolidation in an international, prospective, multicenter phase II trial. J Clin Oncol. 2017;35:536–543. - PubMed
-
- Buxton J, Leen C, Goodlad JR. Polymorphic lymphoid proliferations occurring in HIV‐positive patients: report of a case responding to HAART. Virchows Arch. 2012;461:93–98. - PubMed
Publication types
LinkOut - more resources
Full Text Sources